Table 4.
Prognostic value of combined tumor/plasma KRAS status analyzed by PNA-PCR in a series of 242 metastatic colorectal cancer patients with matched samples
| KRAS status* | Median OS | |||
|---|---|---|---|---|
| Tumor/Plasma | No. | (mo) | 95% Cl | P value |
| Negative/Negative | 113 | 21.0 | 19.226-22.774 | 0.008 |
| Discordant | 65 | 16.9 | 14.184-19.616 | |
| Positive/Positive | 64 | 15.4 | 14.270-16.530 |
*KRAS status was categorized as: negative, mutation-negative tumor and matched plasma samples; discordant, discordant KRAS status in tumor and matched plasma samples; positive, mutation-positive tumor tissue and matched plasma samples.
CI, confidence interval; mo, month; OS, overall survival; PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.